{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:42:18Z","timestamp":1788219738126,"version":"build-2803163510"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease has been recently identified to be a distinct autoimmune central nervous system disorder. There is significant clinical and radiological overlap with multiple sclerosis and aquaporin-4-IgG\u2013associated neuromyelitis optica spectrum disorders. Clinical course is variable in that patients may have a monophasic or relapsing course, disease severity is unpredictable, and unlike other idiopathic autoimmune inflammatory disorders, there is no gender predilection and it is more likely to affect pediatric population. There are no clear-cut treatment guidelines. Duration and dose of oral steroids after the first attack, role of immunosuppressants in relapsing disease, and duration of therapy for the latter are not certain. Currently, there are no disease-specific therapies available, though some novel therapies are under trial. Some of these challenges will be addressed in this paper.<\/jats:p>","DOI":"10.4103\/aian.aian_728_24","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T23:00:07Z","timestamp":1737932407000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Challenges in the Diagnosis and Management of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)"],"prefix":"10.4103","volume":"28","author":[{"given":"Lekha","family":"Pandit","sequence":"first","affiliation":[{"name":"Centre for Advanced Neurological Research, KS Hegde Medical Academy, Nitte University, Mangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"R1-20250220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"R2-20250220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017. revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R3-20250220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R4-20250220","first-page":"423","article-title":"The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane","volume":"66","author":"Lebar","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"R5-20250220","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/01.WNL.0000127615.15768.AE","article-title":"Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects","volume":"62","author":"Lampasona","year":"2004","journal-title":"Neurology"},{"key":"R6-20250220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"key":"R7-20250220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R8-20250220","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol"},{"key":"R9-20250220","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"R10-20250220","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"R11-20250220","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u2019pattern II multiple sclerosis\u2019 and brain biopsy findings in a MOG-IgGpositive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler"},{"key":"R12-20250220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol"},{"key":"R13-20250220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-019-09586-5","article-title":"MOG-IgG-associated demyelination: Focus on atypical features, brain histopathology and concomitant autoimmunity","volume":"267","author":"Papathanasiou","year":"2020","journal-title":"J Neurol"},{"key":"R14-20250220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"R15-20250220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R16-20250220","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"R17-20250220","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense Lesions in AntiMOG-associated Encephalitis with Seizures (FLAMES): Characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J Neurol"},{"key":"R18-20250220","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-20250220","doi-asserted-by":"crossref","first-page":"e200174","DOI":"10.1212\/NXI.0000000000200174","article-title":"Increased intracranial pressure in pediatric myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"11","author":"Nguyen","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R20-20250220","doi-asserted-by":"crossref","first-page":"e200020","DOI":"10.1212\/NXI.0000000000200020","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as intracranial hypertension: A case report","volume":"9","author":"Chaudhuri","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R21-20250220","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"R22-20250220","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-Methyl-D-aspartate receptor encephalitis: Anti-NMDAR encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"R23-20250220","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1212\/NXI.0000000000000538","article-title":"Anti-MOG encephalitis mimicking small vessel CNS vasculitis","volume":"6","author":"Patterson","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R24-20250220","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3389\/fneur.2020.00960","article-title":"The expanding clinical spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody associated disease in children and adults","volume":"11","author":"Parotta","year":"2020","journal-title":"Front Neurol"},{"key":"R25-20250220","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4103\/aian.aian_636_23","article-title":"Cranial nerve involvement apart from optic nerve in MOG-antibody disease: Putative mechanisms","volume":"26","author":"Reddy","year":"2023","journal-title":"Ann Ind Acad Neurol"},{"key":"R26-20250220","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00415-020-10300-z","article-title":"Myelin oligodendrocyte glycoprotein-antibody-associated disorder: A new inflammatory CNS demyelinating disorder","volume":"268","author":"Netravathi","year":"2021","journal-title":"J Neurol"},{"key":"R27-20250220","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1212\/NXI.0000000000000924","article-title":"Overlapping central and peripheral nervous system syndromes in MOG antibody\u2013associated disorders","volume":"8","author":"Rinaldi","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R28-20250220","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/NXI.0000000000000412","article-title":"Reversible paraspinal muscle hyperintensity in anti-MOG antibody\u2013 associated transverse myelitis","volume":"5","author":"Pandit","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R29-20250220","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458520951046","article-title":"MOG-IgG1 and co-existence of neuronal autoantibodies","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler"},{"key":"R30-20250220","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R31-20250220","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R32-20250220","doi-asserted-by":"crossref","first-page":"1192644","DOI":"10.3389\/fneur.2023.1192644","article-title":"High level of agreement in a fixed vs. live cell- based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting","volume":"14","author":"Smith","year":"2023","journal-title":"Front Neurol"},{"key":"R33-20250220","doi-asserted-by":"crossref","first-page":"1252650","DOI":"10.3389\/fimmu.2023.1252650","article-title":"Comparison of live and fixed cell-based assay performance: Implications for the diagnosis of MOGAD in a low-middle income country","volume":"14","author":"Pandit","year":"2023","journal-title":"Front Immunol"},{"key":"R34-20250220","doi-asserted-by":"crossref","first-page":"947630","DOI":"10.3389\/fneur.2022.947630","article-title":"Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort","volume":"13","author":"Manzano","year":"2022","journal-title":"Front Neurol"},{"key":"R35-20250220","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"key":"R36-20250220","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R37-20250220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R38-20250220","first-page":"1","article-title":"MOG-IgG-associated disease has a Stereotypical clinical course, asymptomatic visual impairment and good treatment response","volume":"4","author":"Pandit","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"R39-20250220","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"key":"R40-20250220","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder","volume":"29","author":"Huang","year":"2022","journal-title":"Eur J Neurol"},{"key":"R41-20250220","doi-asserted-by":"crossref","first-page":"102696","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R42-20250220","doi-asserted-by":"crossref","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: A cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_728_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:07:54Z","timestamp":1787774874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_728_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_728_24","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}